The Evidence Base

Every citation, in one place

The atlas is grounded in 868 unique PubMed references. Search the full bibliography, filter to the landmark trials, and jump from any reference to the agents it supports.

868 of 868 references · showing first 80 — search to narrow

Landmark

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Gasowska-Bodnar A et al. · Cancers (Basel) 2026 · PMID 42073552

Niraparib Rucaparib Talazoparib

Landmark

Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naive Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.

Tefferi A et al. · Am J Hematol 2026 · PMID 41504170

Momelotinib

Landmark

BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.

Pour L et al. · Clin Lymphoma Myeloma Leuk 2026 · PMID 42215355

Melphalan flufenamide (melflufen)

Landmark

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.

Huang S, Liu F, Qu S, et al. · Signal Transduction and Targeted Therapy 2026 · PMID 41946687

Penpulimab

Landmark

Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.

McKay RR et al. · Am Soc Clin Oncol Educ Book 2025 · PMID 40198857

Trastuzumab deruxtecan Casdatifan

Landmark

Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.

Pinard L et al. · Clin Lung Cancer 2025 · PMID 40382267

Crizotinib Alectinib Brigatinib Lorlatinib Ceritinib Pralsetinib Capmatinib Tepotinib Repotrectinib

Landmark

Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors.

Izzedine H et al. · Cancer Treat Rev 2025 · PMID 41385991

Abemaciclib Palbociclib Ribociclib

Landmark

Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.

Buijs SM et al. · Br J Cancer 2025 · PMID 39930149

Abemaciclib Palbociclib Ribociclib

Landmark

Drug-induced rise in serum creatinine: cystatin C to the rescue? Evidence, pitfalls and knowledge gaps.

Van Regemorter E et al. · Eur J Intern Med 2025 · PMID 41224604

Capivasertib Repotrectinib

Landmark

Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.

Heymach JV et al. · N Engl J Med 2025 · PMID 40293180

Zongertinib

Landmark

Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.

Rao S et al. · Lancet 2025 · PMID 40517007

Retifanlimab

Landmark

Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy.

Galli E et al. · Eur J Haematol 2024 · PMID 38183299

Thiotepa

Landmark

Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis.

Guarin G et al. · BMC Nephrol 2024 · PMID 39522022

Sacituzumab govitecan

Landmark

Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report.

Sabbah M et al. · Am J Case Rep 2024 · PMID 39482831

Belantamab mafodotin

Landmark

Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.

Chen W et al. · Gynecol Oncol 2024 · PMID 38295607

Niraparib

Landmark

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.

Katoh M et al. · Nat Rev Clin Oncol 2024 · PMID 38424198

Erdafitinib Pemigatinib Futibatinib

Landmark

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.

Wolf J et al. · Lancet Oncol 2024 · PMID 39362249

Capmatinib Tepotinib

Landmark

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Choueiri TK et al. · N Engl J Med 2024 · PMID 39167807

Belzutifan

Landmark

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.

Moslehi JJ et al. · Blood Adv 2024 · PMID 38502198

Zanubrutinib

Landmark

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis.

Jiang H et al. · Hematology 2024 · PMID 39248713

Daratumumab

Landmark

A real-world pharmacovigilance study using disproportionality analysis of FDA Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and vincristine.

Zhong C et al. · Expert Opin Drug Saf 2024 · PMID 39340205

Vincristine Vinblastine Vinorelbine

Landmark

Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.

El-Taji O et al. · JAMA Oncol 2024 · PMID 38842801

Abiraterone Enzalutamide Leuprolide

Landmark

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.

Felip E et al. · Ann Oncol 2024 · PMID 38942080

Amivantamab Lazertinib

Landmark

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Bardia A et al. · J Clin Oncol 2024 · PMID 39265124

Datopotamab deruxtecan (Dato-DXd)

Landmark

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.

Wang ES et al. · Lancet Oncol 2024 · PMID 39362248

Ziftomenib

Landmark

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Foss FM et al. · J Clin Oncol 2024 · PMID 39700456

Denileukin diftitox

Landmark

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

Vergote I et al. · N Engl J Med 2024 · PMID 38959480

Tisotumab vedotin

Landmark

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial (HARMONi-A)

Fang W et al. · JAMA 2024 · PMID 38820549

Ivonescimab

Landmark

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.

Bumma N et al. · J Clin Oncol 2024 · PMID 38879802

Linvoseltamab

Landmark

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Gelderblom H, Bhadri V, Stacchiotti S, et al. · Lancet 2024 · PMID 38843860

Vimseltinib

Landmark

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

Lesokhin AM et al. · Nat Med 2023 · PMID 37582952

Elranatamab

Landmark

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

Rosenberg JE et al. · Ann Oncol 2023 · PMID 37678672

Enfortumab vedotin

Landmark

Deruxtecan-Induced Reversible Fanconi Syndrome.

Kalantri P et al. · Cureus 2023 · PMID 37492824

Trastuzumab deruxtecan

Landmark

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

Moore KN et al. · N Engl J Med 2023 · PMID 38055253

Mirvetuximab soravtansine

Landmark

Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity.

Adegbite BO et al. · Clin J Am Soc Nephrol 2023 · PMID 37382967

Dasatinib

Landmark

Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.

Gross AM et al. · Neuro Oncol 2023 · PMID 37115514

Selumetinib

Landmark

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

Goyal L et al. · N Engl J Med 2023 · PMID 36652354

Futibatinib

Landmark

Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.

Cowan A et al. · J Bone Miner Res 2023 · PMID 36970786

Denosumab

Landmark

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.

Paz-Ares L et al. · J Clin Oncol 2023 · PMID 36689692

Tarlatamab

Landmark

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.

Issa GC et al. · Nature 2023 · PMID 36922593

Revumenib

Landmark

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

Mato AR et al. · N Engl J Med 2023 · PMID 37407001

Pirtobrutinib

Landmark

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Turner NC et al. · N Engl J Med 2023 · PMID 37256976

Capivasertib

Landmark

Nirogacestat, a gamma-Secretase Inhibitor for Desmoid Tumors.

Gounder M et al. · N Engl J Med 2023 · PMID 36884323

Nirogacestat

Landmark

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.

Harding JJ et al. · Lancet Oncol 2023 · PMID 37276871

Zanidatamab

Landmark

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Kilburn LB et al. · Nat Med 2023 · PMID 37978284

Tovorafenib

Landmark

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.

Platzbecker U et al. · Lancet 2023 · PMID 38048786

Imetelstat

Landmark

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.

Wang M et al. · Lancet Respir Med 2023 · PMID 38101437

Sunvozertinib

Landmark

Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter Inhibition.

Nakada T et al. · Drug Metab Dispos 2023 · PMID 36859345

Tucatinib Entrectinib Zongertinib

Landmark

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.

Verstovsek S et al. · J Hematol Oncol 2023 · PMID 37501130

Ruxolitinib

Landmark

ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.

Duminuco A et al. · Cancers (Basel) 2023 · PMID 38201581

Momelotinib

Landmark

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Erba HP et al. · Lancet 2023 · PMID 37116523

Quizartinib Idarubicin

Landmark

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

de Botton S et al. · Blood Adv 2023 · PMID 36724515

Olutasidenib

Landmark

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

Shah MA et al. · Nat Med 2023 · PMID 37524953

Zolbetuximab

Landmark

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.

Mai HQ et al. · JAMA 2023 · PMID 38015220

Toripalimab

Landmark

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.

Clingan P, Ladwa R, Brungs D, et al. · Journal for Immunotherapy of Cancer 2023 · PMID 37848259

Cosibelimab

Landmark

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. · N Engl J Med 2023 · PMID 37272516

Vorasidenib

Landmark

Cisplatin nephrotoxicity: new insights and therapeutic implications.

Tang C et al. · Nat Rev Nephrol 2022 · PMID 36229672

Cisplatin

Landmark

Teclistamab in Relapsed or Refractory Multiple Myeloma.

Moreau P et al. · N Engl J Med 2022 · PMID 35661166

Teclistamab

Landmark

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.

Chari A et al. · N Engl J Med 2022 · PMID 36507686

Talquetamab

Landmark

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.

Budde LE et al. · Lancet Oncol 2022 · PMID 35803286

Mosunetuzumab

Landmark

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Thieblemont C et al. · J Clin Oncol 2022 · PMID 36548927

Epcoritamab

Landmark

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Dickinson MJ et al. · N Engl J Med 2022 · PMID 36507690

Glofitamab

Landmark

Anaplastic lymphoma kinase inhibitors and their effect on the kidney.

Bonilla M et al. · Clin Kidney J 2022 · PMID 35892021

Crizotinib Alectinib Brigatinib Lorlatinib Ceritinib

Landmark

Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.

Ahn L et al. · Clin J Oncol Nurs 2022 · PMID 36108212

Capmatinib Tepotinib

Landmark

Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity.

García-Carro C et al. · Nephron 2022 · PMID 35717937

Sotorasib Adagrasib Zanubrutinib Ribociclib Topotecan Paclitaxel Docetaxel Cabazitaxel Eribulin

Landmark

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation.

Jänne PA et al. · N Engl J Med 2022 · PMID 35658005

Adagrasib

Landmark

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.

Pemmaraju N et al. · J Clin Oncol 2022 · PMID 35820082

Tagraxofusp

Landmark

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.

Hulshof EC et al. · Eur J Hum Genet 2022 · PMID 36443464

Irinotecan

Landmark

Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.

Mercier F et al. · Cancer Chemother Pharmacol 2022 · PMID 35118559

Entrectinib

Landmark

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Bidard FC et al. · J Clin Oncol 2022 · PMID 35584336

Elacestrant

Landmark

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

Tawbi HA et al. · N Engl J Med 2022 · PMID 34986285

Relatlimab

Landmark

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.

Shen L, Kato K, Kim SB, et al. · Journal of Clinical Oncology 2022 · PMID 35442766

Tislelizumab

Landmark

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.

Jiang Q et al. · Journal of Hematology & Oncology 2022 · PMID 35982483

Olverembatinib

Landmark

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.

Zhou C et al. · The Lancet Oncology 2022 · PMID 35038432

Sugemalimab

Landmark

BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells.

Sanagawa A et al. · Anticancer Drugs 2021 · PMID 34232935

BRAF / MEK Inhibitors Encorafenib Cobimetinib Binimetinib Selumetinib

Landmark

Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update.

Nervo A et al. · Crit Rev Oncol Hematol 2021 · PMID 34801702

Lenvatinib Cabozantinib Vandetanib Tivozanib

Landmark

Nintedanib-Induced Renal Thrombotic Microangiopathy.

Fujita T et al. · Case Rep Nephrol Dial 2021 · PMID 34414215

Nintedanib

Landmark

Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy.

Hakroush S et al. · Front Oncol 2021 · PMID 34912725

Trastuzumab emtansine (T-DM1)Datopotamab deruxtecan (Dato-DXd)

Landmark

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Tilly H et al. · N Engl J Med 2021 · PMID 34904799

Polatuzumab vedotin

Citation metadata via PubMed / the U.S. National Library of Medicine, which does not endorse this site. Educational reference only — not medical advice.